Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial - Archive ouverte HAL Access content directly
Journal Articles Lung Cancer Year : 2021

Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial

(1) , (2, 3) , (4) , (5) , (6) , (7) , (8) , (8) , (8) , (9) , (10) , (10) , (8) , (1)
1
2
3
4
5
6
7
8
9
10

Abstract

Therapies targeting immune checkpoints, such as the programmed cell death 1 (PD-1) receptor, have become the standard-of-care for patients with non-small cell lung cancer (NSCLC), but people living with HIV (PLWH) were excluded from these studies.
EudraCT.ema.europa.eu registration number: 2016-003796-22.
Not file

Dates and versions

hal-03524445 , version 1 (13-01-2022)

Identifiers

Cite

Armelle Lavole, Julien Mazieres, Sophie Schneider, Solenn Brosseau, Lize Kiakouama, et al.. Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer, 2021, 158, pp.146-150. ⟨10.1016/j.lungcan.2021.05.031⟩. ⟨hal-03524445⟩
29 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More